Company Reports

Repligen is a leading provider of bioprocessing solutions for companies that manufacture biologic drugs. Its business lines include advanced filtration and fluid management systems for both upstream and downstream processes, prepacked chromatography columns, proteins used in chromatography resins, and process analytic systems. Although Repligen is a relatively small player, we believe it is at the forefront of the innovation frontier. In the past 10 years, it has transformed from a company mostly known for its protein A ligands to one with a record of launching new products with limited or no direct competition.

Repligen reported second-quarter year-on-year organic revenue growth of 13% and adjusted EBITDA margin expansion of 3.8 percentage points. Management raised 2026 guidance for organic revenue growth to 10.5%-13.5% from 9.0%-13.0% and adjusted EBITDA margin to 20.6%-21.0% from 20.3%-20.8%.

Repligen is a leading provider of bioprocessing solutions for companies that manufacture biologic drugs. Its business lines include advanced filtration and fluid management systems for both upstream and downstream processes, prepacked chromatography columns, proteins used in chromatography resins, and process analytic systems. Although Repligen is a relatively small player, we believe it is at the forefront of the innovation frontier. In the past 10 years, it has transformed from a company mostly known for its protein A ligands to one with a record of launching new products with limited or no direct competition.

Repligen reported year-over-year organic revenue growth of 11% and adjusted EBITDA margin of 20.6%, an expansion of 130 basis points. For 2026, management reiterated guidance for organic revenue growth of 9% to 13% and raised guidance for adjusted EBITDA margin by 30 basis points to 20.3 to 20.8%.

Repligen reported year-on-year revenue growth of 14% for the quarter and 16% for the year. Full-year adjusted EBITDA margin was 19%, or 50 basis points better than last year. Management's guidance for 2026 includes 9% to 13% organic revenue growth and adjusted EBITDA margin of 20.0% to 20.5%.

Narrow-moat-rated Repligen is a leading provider of bioprocessing solutions for companies that manufacture biologic drugs. Its business lines include advanced filtration and fluid management systems for both upstream and downstream processes, prepacked chromatography columns, proteins used in chromatography resins, and process analytic systems. Although Repligen is a relatively small player, we believe it is at the forefront of the innovation frontier. In the past 10 years, it has transformed from a company mostly known for its protein A ligands to one with a track record of launching new products with limited or no direct competition.

Repligen reported year-on-year revenue growth of 22% and adjusted operating margin of 14.2%, which is 70 basis points worse than the same period last year. The company narrowed its full-year guidance ranges and slightly raised its midpoint for revenue growth by 1 percentage point.

Repligen reported second-quarter year-on-year revenue growth of 15% and an adjusted operating margin of 12%, which is 80 percentage points worse than the same period last year. It significantly raised its full-year guidance for revenue growth to 14.5% at the midpoint, or 3 percentage points higher.

Repligen reported year-on-year revenue growth of 10% and an adjusted operating margin of 13.8%, which is 4.9 percentage points better than the same period last year. The company refreshed its full-year guidance ranges, with slightly better revenue offset by slightly worse margins.

Narrow-moat Repligen’s fourth-quarter earnings were in line with our expectations, and guidance for next year suggests an encouraging return to growth and margin expansion. Although we had hoped for slightly more adjusted margin improvement, the company’s financial metrics are moving in the right direction, and we think it is well on its way to returning to normalized double-digit revenue growth and steadily improving profitability. We maintain our fair value estimate of $180 per share.

Narrow-moat-rated Repligen is a leading provider of bioprocessing solutions for companies that manufacture biologic drugs. Its business lines include advanced filtration and fluid management systems for both upstream and downstream processes, prepacked chromatography columns, proteins used in chromatography resins, and process analytic systems. Although Repligen is a relatively small player, we believe it is at the forefront of the innovation frontier. In the past 10 years, it has transformed from a company mostly known for its protein A ligands to one with a track record of launching new products with limited or no direct competition.

Narrow-moat Repligen's third-quarter results exceeded our expectations. Full-year guidance was in line with previous communications, albeit with narrowed ranges, and we think the company's return to normalized growth rates of high single digits or low teens is well under way. The company provided restated financials for the past six quarters to correct for the timing of revenue recognition of a $17.3 million contract cancellation payment received in April 2023. We view the impact of these restatements as immaterial to our prior analysis of the company, and it does not affect our outlook for it going forward. We maintain our fair value estimate of $180 per share and view the stock as modestly undervalued at current market prices.

We are initiating coverage of Repligen with a narrow moat rating and fair value estimate of $180 per share. The firm is a leading provider of bioprocessing solutions for companies manufacturing biologic drugs, and its business lines include advanced filtration and fluid management systems, prepacked chromatography columns, proteins used in chromatography resins, and process analytic systems. We view the shares as modestly undervalued at current market prices.

Narrow-moat-rated Repligen is a leading provider of bioprocessing solutions for companies that manufacture biologic drugs. Its business lines include advanced filtration and fluid management systems for both upstream and downstream processes, prepacked chromatography columns, proteins used in chromatography resins, and process analytic systems. Although Repligen is a relatively small player, we believe it is at the forefront of the innovation frontier. In the past 10 years, it has transformed from a company mostly known for its protein A ligands to one with a track record of launching new products with limited or no direct competition.